FDA clears new generic weekly menopause patch - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA clears new generic weekly menopause patch

The once-weekly patch provides a generic alternative for menopausal symptoms and osteoporosis prevention.

  • By

  • Mouj Hijazi

  • October 21, 2026

  • 2 min

Share

  • 1

    The FDA approved the first generic estradiol and levonorgestrel transdermal system, manufactured by Zydus Pharmaceuticals.

  • 2

    The once-weekly patch delivers estradiol 0.045 mg per day and levonorgestrel 0.015 mg per day.

  • 3

    The generic is therapeutically equivalent to Climara Pro and has the same approved uses for women with an intact uterus.

  • 4

    The patch is approved for moderate to severe menopausal vasomotor symptoms and prevention of postmenopausal osteoporosis.

  • 5

    The FDA announcement did not report commercial availability, pricing, or new comparative efficacy trial results.

Original Source(s)

FDA clears new generic weekly menopause patch

  • by Mouj Hijazi

  • October 21, 2026

Related Content

A self-care smartphone application for midlife women with menopausal symptoms: A proof-of-concept study

Point-of-care ultrasound in obstetrics and gynecology: latest advancements and evolution

Menopause may be underdocumented in EHRs

Surveys captured nearly 7 times as many menopause observations as structured clinical records, with high agreement when both sources identified menopause.